Shigehiro Yagishita

The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer

Yu Fujita, Shigehiro Yagishita, Keitaro Hagiwara et al. · Molecular Therapy · 2015 · 262 citations · Full text

Medicine, Cancer Biology, Oncology +17

Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial

Tadaaki Nishikawa, Kosei Hasegawa, Koji Matsumoto et al. · Journal of Clinical Oncology · 2023 · 127 citations · Full text

Medicine, Oncology, Pharmacology +17

A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies

Kenta Noda, Kouki Matsuda, Shigehiro Yagishita et al. · Scientific Reports · 2021 · 70 citations · Full text

Life Sciences, Immunology, Infectious Diseases +16

Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells

Isao Kobayashi, Fumiyuki Takahashi, Fariz Nurwidya et al. · Biochemical and Biophysical Research Communications · 2016 · 69 citations

Life Sciences, Molecular Biology, Oncology +14

Epidermal Growth Factor Receptor Mutation Is Associated With Longer Local Control After Definitive Chemoradiotherapy in Patients With Stage III Nonsquamous Non–Small-Cell Lung Cancer

Shigehiro Yagishita, Hidehito Horinouchi, Tomoko Taniyama et al. · International Journal of Radiation Oncology*Biology*Physics · 2014 · 62 citations

Medicine, Oncology, Radiation Oncology +14